Abstract
Aumolertinib (aumo), a third-generation (3rd gen) EGFR inhibitor (EGFRi), is being developed as a first-line treatment (1L tx) for patients with advanced EGFR mutation-positive (EGFR+) NSCLC. Osimertinib (osi) is a widely used 3rd gen EGFRi for 1L tx of EGFR+ NSCLC. Although both aumo and osi have demonstrated superior safety and efficacy to earlier generation EGFRis in clinical trials, no direct comparison of efficacy and safety has been done. The objective of this analysis was to compare progression-free survival (PFS), overall survival (OS), and any-grade treatment-emergent adverse events (AG-TEAE) for aumo vs osi utilizing an anchored indirect treatment comparison (ITC).
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
